OCA at 05:39, 31 May 2023

OCA — Wed, 31 May 2023 05:39:28 GMT

←Older revision		Revision as of 05:39, 31 May 2023
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 8cyr is ~~ON HOLD~~ ~~until Paper Publication~~	+	==Alpha-synuclein fibril from spontaneous control==
-		+	<StructureSection load='8cyr' size='340' side='right'caption='[[8cyr]], [[Resolution\|resolution]] 4.20Å' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[8cyr]] is a 12 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8CYR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8CYR FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8cyr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8cyr OCA], [https://pdbe.org/8cyr PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8cyr RCSB], [https://www.ebi.ac.uk/pdbsum/8cyr PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8cyr ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
		+	== Disease ==
		+	[https://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN] Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1. Defects in SNCA are the cause of Parkinson disease type 1 (PARK1) [MIM:[https://omim.org/entry/168601 168601]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.<ref>PMID:9197268</ref> <ref>PMID:9462735</ref> <ref>PMID:14755719</ref> Defects in SNCA are the cause of Parkinson disease type 4 (PARK4) [MIM:[https://omim.org/entry/605543 605543]. A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia. Defects in SNCA are the cause of dementia Lewy body (DLB) [MIM:[https://omim.org/entry/127750 127750]. A neurodegenerative disorder clinically characterized by mental impairment leading to dementia, parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN] May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Homo sapiens]]
		+	[[Category: Large Structures]]
		+	[[Category: Bartesaghi A]]
		+	[[Category: Borgnia M]]
		+	[[Category: Bouvette J]]
		+	[[Category: Dillard L]]
		+	[[Category: Li JY]]
		+	[[Category: Matarangas A]]
		+	[[Category: Sokratian A]]
		+	[[Category: Viverette E]]
		+	[[Category: West A]]
		+	[[Category: Xu E]]
		+	[[Category: Yuan Y]]
		+	[[Category: Zhou Y]]

OCA at 06:25, 29 June 2022

OCA — Wed, 29 Jun 2022 06:25:47 GMT

←Older revision		Revision as of 06:25, 29 June 2022
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 8cyr is ON HOLD	+	The entry 8cyr is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "8cyr" [edit=sysop:move=sysop]

OCA — Wed, 08 Jun 2022 04:28:13 GMT

Protected "8cyr" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:28, 8 June 2022

OCA: New page: '''Unreleased structure''' The entry 8cyr is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 08 Jun 2022 04:28:12 GMT

New page: '''Unreleased structure''' The entry 8cyr is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 8cyr is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]

8cyr - Revision history

OCA at 05:39, 31 May 2023

OCA at 06:25, 29 June 2022

OCA: Protected "8cyr" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 8cyr is ON HOLD Authors: Description: Category: Unreleased Structures